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Chikungunya  virus  (CHIKV)  is  an  arthritogenic  alphavirus  that  during  the last  decade  has  signiﬁcantly
expanded  its geographical  range  and  caused  large  outbreaks  of  human  disease  around  the  world.  Althougheywords:
hikungunya
lphavirus
olyarthralgia
accine
merging disease
mortality  rates  associated  with  CHIKV  outbreaks  are  low,  acute  and  chronic  illnesses  caused  by  CHIKV
represent  a signiﬁcant  burden  of  disease  largely  affecting  low  and  middle  income  countries.  This report
summarizes  the current  status  of  vaccine  development  for  CHIKV.
© 2016  World  Health  Organization;  licensee  Elsevier  Ltd.  This  is  an open  access  article  under  the  CC
BY  license  (http://creativecommons.org/licenses/by/3.0/).. About the disease and pathogen
Chikungunya fever, a mosquito transmitted disease caused by
hikungunya virus (CHIKV), is an acute febrile illness character-
zed by severe, debilitating polyarthralgia, that often progresses
o a chronic stage, with reports of over 60% of those affected
uffering from joint pain three years after infection. Unlike sim-
lar arboviral diseases such as dengue, infection with CHIKV is
arely asymptomatic with less than 5–25% of patients reported
s having seroconverted without symptoms during recent large
pidemics. Disease occurs across all age groups with similar fre-
uencies and is associated with fever and severe myalgia (90% of
atients), polyarthralgia and polyarthritis (95%), and rash (50%).
evere but rare manifestations include encephalopathy, encephali-
is, myocarditis, hepatitis, multi-organ failure and death. These are
ypically associated with older age and pre-existing morbidities
uch as cardiovascular or neurologic disease, respiratory disorders,
r diabetes. Neonates and young children may  also experience
igher incidence of severe chikungunya disease. Following the
cute phase of febrile disease, roughly half of patients experience
hronic joint pain that may  persist or recur in cycles over several
∗ Corresponding author.
E-mail addresses: dwbeasle@utmb.edu, d.beasley@utmb.edu (D.W.C. Beasley).
1 These authors made equal contributions to the preparation of this report.
ttp://dx.doi.org/10.1016/j.vaccine.2016.03.076
264-410X/© 2016 World Health Organization; licensee Elsevier Ltd. This is an open acceyears. Chronic symptoms can be similar to those of seronegative
rheumatoid arthritis, frequently resulting in persistent incapac-
itation, often requiring long-term treatment using non-steroidal
anti-inﬂammatory and immunosuppressive drugs. There are no
antiviral treatments currently available [1,2].
CHIKV is an enveloped, positive-sense single stranded RNA
alphavirus in the family Togaviridae. Like most alphaviruses, CHIKV
has the ability to infect and replicate in both vertebrates and
invertebrates, allowing for maintenance of the virus in enzootic
cycles between its non-human primate reservoir and arboreal
mosquitoes, with occasional transmission to human populations.
However, unlike most alphaviruses, CHIKV utilizes an urban cycle
resulting in sustained transmission between humans and anthro-
pophilic mosquitoes causing widespread epidemics with attack
rates reaching 90%. Over the past decade CHIKV has emerged as
a major cause of vector-borne disease with transmission reported
in more than 100 countries and territories worldwide. Globally,
there are an estimated 1 million cases per year including periodic
large-scale epidemic outbreaks throughout the world and low-
level endemic transmission in Africa and Southeast Asia [3,4]. Large
epidemics occur episodically and unpredictably and tend to be
explosive. For example, in 2004, CHIKV reemerged in Lamu Island,
Kenya, resulting in 1300 documented clinical cases and potentially
infected over 70% of the population. In 2005, CHIKV infected 63%
of Union of the Comoros’ population resulting in 225,000 cases. In
2006, there were 266,000 cases on the island of La Réunion (approx.
ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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mately 1–2 weeks. Neutralizing antibodies offer protection against
CHIKV infection/disease in humans and in animal models and per-C. Smalley et al. / Vac
/3 of population) with the ﬁrst signiﬁcant reports of neurologi-
al symptoms and fatal cases. Similar large epidemics, with over
 million estimated cases, occurred in southern India during
005–2006. An ongoing epidemic spreading throughout the Amer-
cas began in December of 2013 and, as of May  2015, has resulted in
ver 1.4 million suspected cases across 50 countries and territories,
ith 178 associated deaths [5].
While the estimated case fatality rate is low (∼0.1–5% reported
n recent epidemics) compared to some other arboviral diseases
f global importance, the economic and disease burden due to
he severe morbidity of chikungunya fever appears substantial,
lthough only a few studies to evaluate costs of chikungunya dis-
ase have been performed and additional data are needed. The
a Reunion outbreak in 2006 resulted in an estimated US$50–55
illion in medical costs [6] and 55,000 DALYs when accounting
or acute and long term disease [7]. A recent prospective cohort
tudy of acute febrile illnesses in children at study sites in sev-
ral Southeast Asian countries determined that CHIKV infection
as responsible for approximately 3-fold higher number of cases
ompared to dengue viruses [8], although this may  be an over-
stimate due to the limited conﬁrmatory testing performed on
nti-CHIKV IgM positive samples. Similar hospital-based stud-
es during 2008–2009 in India identiﬁed CHIKV as the cause
f almost 50% of acute febrile illnesses in the southern state
f Karnataka [9], an area greatly affected by the 2005–2006
pidemics.
Four lineages of CHIKV currently circulate throughout the
orld: the East, Central, and Southern African (ECSA) lineage, the
est African lineage, the Asian lineage, and the Indian Ocean
ineage (IOL). While the ECSA and Asian lineages are typically trans-
itted by the urban vector, A. aegypti,  the IOL is characterized
y acquired adaptive mutations in the E1/E2 proteins allowing
or sustained transmission by the more widespread A. albopictus
rban mosquito. It was  thought that IOL CHIKV may  become pre-
ominant due to this adaptation and its association with large
utbreaks in 2005–2008. However, the ongoing outbreak in the
mericas (associated with strains belonging to the Asian lineage),
nd the emergence and spread of Asian and ECSA lineages in the
outh Paciﬁc since 2011, highlight the epidemic potential of all
HIKV variants. Animal studies suggest that there is no major
ifference in virulence between CHIKV strains representing the dif-
erent lineages. Recent reports from Southeast Asia [10] and the
mericas have described higher than typical rates of subclinical
HIKV infection leading to suggestions that there may  be lineage-
r strain-speciﬁc differences in virulence, although pre-existing
mmunity in Asia may  also have inﬂuenced subclinical infection
ates.
Presumptive diagnosis is typically clinical with conﬁrmatory
aboratory tests performed using serum samples. If samples are
ollected within 5 days of fever onset, reverse transcription poly-
erase change reaction (RT-PCR) can be used to detect viral
enome. For RT-PCR negative samples collected 5 or more days
fter onset, enzyme-linked immunosorbent assays (ELISAs) can
e performed to detect anti-CHIKV IgM antibodies. Several IgM-
LISA kits are commercially available. Since other alphaviruses
elonging to the same antigenic complex as CHIKV, such as
ayaro, o’nyong-nyong, and Ross River viruses, co-circulate in
reas where CHIKV transmission has occurred, there is potential
or cross-reactivity when performing ELISAs. Conﬁrmatory sero-
ogical testing via plaque reduction neutralization test (PRNT) for
LISA-positive, RT-PCR-negative samples is performed at reference
aboratories.
To date, vector control has been the primary response to
hikungunya outbreaks but effectiveness has not been extensively
valuated and may  face challenges due to insecticide resistance in
edes spp. vectors.4 (2016) 2976–2981 2977
2. Overview of current efforts
2.1. Biological feasibility for vaccine development
There are no licensed vaccines for chikungunya. However, sev-
eral other alphavirus vaccine candidates have been evaluated in
human clinical trials or licensed for veterinary use, including for
Ross River virus (RRV) and Venezuelan equine encephalitis (VEEV)
among others. The RRV candidate and the veterinary vaccines are
based on an inactivated-virus platform, and a live, attenuated VEEV
vaccine has been used for special immunization in the United
States under an investigational new drug (IND) approval. Protective
immunity induced by each of these vaccines is believed to be asso-
ciated with induction of neutralizing antibodies directed towards
the envelope glycoproteins.
All CHIKV lineages appear to comprise a single serotype and
it appears that long-lasting cross-protection between lineages is
afforded, so a single vaccine can be expected to protect against all
CHIKV strains. A formalin inactivated chikungunya vaccine candi-
date was  developed by the US military in the 1960s. Due to concerns
about cost and safety of bulk production of CHIKV at BSL3, a live,
empirically attenuated candidate, TSI-GSD-218 (strain 181/clone
25, derived from Asian lineage strain AF15561) was subsequently
developed during the 1980s-90s by the US Army Medical Research
Institute for Infectious Diseases (USAMRIID) and evaluated in Phase
I/II clinical trials. This vaccine displayed strong immunogenic-
ity (>98% seroconversion) and was generally well tolerated with
only mild effects, including transient arthralgia in approx. 10% of
recipients. Further development of this vaccine was discontinued,
primarily due to low priority of chikungunya to the military cou-
pled with signiﬁcant perceived challenges for further development
and clinical efﬁcacy trials. The live, attenuated virus was provided
to other vaccine developers following resurgence of chikungunya
in the mid-2000s. Reversion to virulence is a concern for this vac-
cine as subsequent studies showed attenuation was  mediated by
only two  point mutations.
Several animal models are available to study chikungunya dis-
ease and to assess vaccine efﬁcacy. The model that most closely
mimics the human disease is cynomolgus macaques, which are a
natural reservoir of the virus and show a dose dependent patho-
physiology. Low infecting doses (101 pfu) result in viremia, fever
and rash while higher doses (>106 pfu) can also result in joint
swelling and meningoencephalitis, similar to severe disease seen
in humans. Immunocompetent mice (e.g. C57BL/6, ICR, or CD1) do
not mimic  the human disease and show an age-dependent suscep-
tibility. Suckling mice are susceptible to a neuroinvasive disease.
Disease in mice greater than 3–4 weeks of age is characterized by
transient viremia and swelling at the site of inoculation, typically
the footpad. Those two parameters are typically used as endpoints
to assess protection in challenge studies. Immunocompromised
mice, particularly IFN-/ receptor knockouts (e.g. A129) exhibit
more severe disease, including mortality, and may  more accurately
mimic  the cell/tissue tropism of CHIKV infection in humans.
The current understanding of protective immune responses to
CHIKV infection has been derived from animal models as well as
limited human data following natural infection [11]. The humoral
immune response seems to play a more important role in control-
ling CHIKV infection than cell mediated immunity (CMI). Following
CHIKV infection in humans and nonhuman primates (NHPs), the
incubation period is typically 3–7 days (range 1–12 days) and IgM
antibodies can be detected approximately 2–3 days after onset of
symptoms, followed by production of IgG antibodies at approxi-sist for many years after infection in humans. Epitope mapping
studies with human sera and monoclonal antibodies have identiﬁed
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inear and conformation-dependent epitopes in the E1/E2 glyco-
roteins, particularly in the region of the exposed trimer spike,
hat are targets of strongly neutralizing antibodies. It has also been
uggested that early production of neutralizing IgG3 antibodies
n particular may  protect against chronic arthralgia in humans
12]. Signiﬁcantly, passive immunization experiments in mouse
odels using neutralizing serum [13] or monoclonal antibodies,
onvalescent human serum, or post-vaccination NHP serum have
emonstrated protection against viremia and/or disease, suggest-
ng that neutralizing antibodies are a likely correlate of protection.
n ongoing phase I/II clinical trial (clinicaltrials.gov NCT02230163)
s investigating the use of anti-CHIKV hyperimmune intravenous
mmunoglobulin for therapy of neonates at risk of exposure to
HIKV during childbirth. However, only limited enrollment (4 of
 planned 40 subjects) has been reported to date [14].
Although CMI  is likely to be important for developing durable
rotective immunity following vaccination, speciﬁc roles for cel-
ular responses in protection or resolution of disease are not well
eﬁned [11]. CD8T cells have been shown to play a role in con-
rolling natural acute infections in humans, but adoptive transfer
f T lymphocytes in mouse models has suggested that cellular
esponses are not necessary for protection [13]. There is some
vidence from studies in immunocompromised mouse models
howing involvement of CD4T cells in pathology of chikungunya
isease, leading to a suggestion that a vaccine that induces a T-cell
esponse in the absence of a robust antibody response could con-
ribute to immunopathology [15]. More work is needed to clearly
eﬁne the role of CMI  in protection and/or immunopathology.
.2. General approaches to vaccine development for CHIK for low
nd middle income country (LMIC) markets
At present there does not appear to be a strong consensus
egarding the potential deployment of a licensed chikungunya
accine in LMIC, although it would most likely be either as
art of outbreak response or in vaccination campaigns and/or
s part of a standard immunization schedule in endemic areas.
andidate vaccines could be expected to be used in adult and
ediatric populations. Vaccine developers/manufacturers in LMIC,
rimarily in India, have focused on the development of inactiv-
ted candidates, which will most likely require multiple doses
nd subsequent boosting to develop and maintain immunity (see
ection IV) but may  have better thermostability and be more
menable to a controlled temperature chain than live attenuated
r vectored candidates. However, other vaccine candidates include
otential single-dose formulations that may  be more appropri-
te for use in outbreak response scenarios or targeted vaccination
ampaigns. Each of the different vaccine approaches under devel-
pment has potential advantages and limitations for LMIC use in
erms of e.g. dosing requirements, cost of production, stability,
nd durability of immunity. For this reason, deﬁnition of preferred
roduct characteristics of a chikungunya vaccine, particularly con-
ensus on the optimal vaccination strategy, would be helpful in
roduct development planning and supporting the investment
ase.
As described in Section I above, the burden of disease associ-
ted with chikungunya epidemics, and with endemic transmission
n some areas, is signiﬁcant even compared to other arboviral dis-
ases such as dengue, so an effective chikungunya vaccine can be
xpected to provide signiﬁcant public health beneﬁt.. Technical and regulatory assessment
Many of the chikungunya vaccine candidates under develop-
ent utilize platforms or approaches that have precedents for4 (2016) 2976–2981
regulatory approval. The most probable path forward for vaccine
candidates is demonstration of ﬁeld efﬁcacy via traditional clinical
trials. However, due to the unpredictable, focal and periodic nature
of chikungunya outbreaks, Phase II/III randomized controlled trials
in humans to demonstrate vaccine efﬁcacy are likely to be logis-
tically challenging. Endpoints for clinical efﬁcacy studies would
include prevention or reduction of symptomatic illness and induc-
tion of neutralizing antibodies. Licensure based on neutralizing
antibody titer as a correlate of protection may  be plausible and
the majority of vaccine candidates appear to be focused towards
induction of antibody responses against viral structural proteins,
particularly E1 and E2. No speciﬁc minimum protective titers have
been robustly established, although one passive protection study
in A129 mice reported PRNT50 ≥ 35 as protective [13]. It has also
been suggested that the United States Food and Drug Adminis-
tration’s (FDA) Animal Rule may  represent a path to licensure for
chikungunya vaccines [16]. However, this seems unlikely given the
scope and application of the Animal Rule (“serious or life threat-
ening conditions” that are “lethal or permanently disabling”) and
the limitations of many current models to mimic  the outcomes of
human infection.
Assays employed to measure humoral immunity following
vaccination have typically included ELISA and plaque reduction
neutralization. The individual methodology for each assay varies
widely across studies, with signiﬁcant differences in key assay
parameters (e.g. virus/antigen type, incubation times and tem-
peratures, cell substrates) and endpoints (e.g. 50%, 80%, or 90%
neutralization). Standardization of protocols for assessment of neu-
tralizing and total antibody responses and/or the development
of standardized antibody/antiserum reference reagents are nec-
essary to facilitate direct comparisons of the multiple vaccine
candidates in the pipeline and to establish antibody titer(s) that
correlate with protection. In addition to total and neutralizing
antibody titers, several studies have assessed qualitative and quan-
titative aspects of cell mediated immunity using T-cell based assays
such as intracellular cytokine staining and ELISpot. Further stud-
ies are needed to assess the contribution of cellular immunity to
protection from chikungunya disease following vaccination and
if/how that will be measured in clinical studies to aid in vaccine
licensure.
4. Status of vaccine R&D activities
The chikungunya vaccine pipeline appears robust [17]. More
than 15 vaccine candidates based on a range of platforms (inactiv-
ated, live attenuated, live vectored, chimeric, virus-like particle
[VLP], subunit protein, DNA) are currently in preclinical and
clinical development and several in collaboration with indus-
try (Table 1). Many candidates utilize CHIKV structural proteins
delivered by recombinant viral or plasmid vectors or prepared
as subunit/VLP antigens, and most been shown to induce strong
humoral responses in mice, rabbits and guinea pigs as well as non-
human primates often without exogenous adjuvants. The durability
of protective immunity induced by many of these candidates is
currently uncertain but detection of neutralizing antibodies 6–12
months post-vaccination in mice or NHPs has been reported for
several candidates. A majority of the peer reviewed literature
relating to new chikungunya vaccine candidates has emerged in
the last 5 years and two  candidates have recently completed
Phase I testing. These and some other candidates are described
below.The ﬁrst new candidate to reach Phase I trials was  a VLP vac-
cine, which had shown strong immunogenicity and protection
against CHIKV challenge in mice and NHPs. VRC-CHKVLP059-
00-VP comprised VLPs expressed from VRC293 cells transfected
C. Smalley et al. / Vaccine 34 (2016) 2976–2981 2979
Table  1
Development status of current vaccine candidates (POC = proof of concept trial).
Candidate name/identiﬁer Developer Type/platform Preclinical Phase 1 Phase 2 POC  Phase 3
TSI-GSD-218
(Thailand/1556) 2E2
USAMRIID/Salk Institute
for Biological Studies
Live,
attenuated
X
VRC-CHKVLP059-00-VP
(37997)
National Institute of
Allergy and Infectious
Diseases (NIAID)
VLP X
Formalin inactivated
(Thailand/1556)
U.S. Army Medical
Research Institute of
Infectious Diseases
(USAMRIID)
Inactivated,
whole virus
X
MV-CHIK (Measles virus
vector)
Themis Bioscience
GmbH/Institut Pasteur
Live,
vectored
X 2016
Formalin inactivated,
multiple Indian CHIKV
isolates 2006–2010
Bharat Biotech
International
Inactivated,
whole virus
X 2016
Formalin inactivated
CHIKV181/25
Indian Immunologicals Ltd.
(virus from US Army
Medical Research and
Material Command
(USAMRMC))
Inactivated,
whole virus
X 2016
CHIKV-IRES (v1/v2) Takeda Pharmaceuticals
U.S.A., Inc./University of
Texas Medical Branch
(UTMB)
Live,
attenuated
X
Chimeric Alphavirus
(VEEV, EEV, SINV, or EILV
genetic backbones)
University of Alabama at
Birmingham (UAB)/UTMB
Live,
attenuated
X
CHIKV-5nsP3  Valneva/Karolinska
Institutet (also
CHIKV-6K)
Live,
attenuated
X
TM17-2  Arbovax, Inc./North
Carolina State University
(NCSU)
Live,
attenuated
X
VSVG-CHIKV (VSV
vectored)
Profectus Biosciences/Yale
University/UTMB
Live,
vectored
X
Vaccinia [Ankara]-Vectored
(MVA-CHIKV E1E26KE3)
Karolinska Institutet/CSIC
Madrid
Live,
vectored
X
Vaccinia vectored
(MVA-CHIKV E2E3)
University of Wisconsin-
Madison/Takeda
Pharmaceuticals U.S.A., Inc.
Live,
vectored
X
Recombinant Adenovirus
(CAdVax-CHIKV)
GenPhar, Inc. Live,
vectored
X
CHIKV DRDE-06 (Indian)
Formalin inactivated
Defense Research and
Development Organisation
(DRDE), India
Inactivated,
whole virus
X
Formalin inactivated –
Nanotherapeutics
(Transferred from Baxter
U.S. in late 2014)
Inactivated,
whole virus
X
p181/25-7CHIKV iDNA Medigen, Inc. DNA X
CHIKV-Env + pnsP2; CHIKV
pMCE321
Inovio
Pharmaceuticals/VGXTM
Animal Health/University
of Pennsylvania
DNA X
rCHIK-E1/E2 (DRDE-06)
E. coli
DRDE, India Subunit X
rE2-CHIK National Institute of
Virology, India
Subunit X
VLP  -CHIKV-S27 TI Pharma/Wageningen
University
VLP X
S lted o
A d that
w
f
s
s
(
w
b
t
a
t
dhaded boxes indicate that further development of this candidate/type has been ha
 small number of additional subunit or DNA vaccine candidates have been reporte
ith plasmid encoding structural protein genes (C-E3-E2-6K-E1)
rom CHIKV strain 37997 (West African lineage). The Phase I
tudy in healthy adults reported an excellent safety proﬁle and
trong immunogenicity for low (10 g), medium (20 g) and high
40 g) dose cohorts (3 intramuscular [i.m.] immunizations each,
ithout adjuvant, at 0, 4 and 20 weeks) [18]. Neutralizing anti-
odies were detected in all subjects following the second dose,
iters peaked 4 weeks after the third dose (IC 4525–8745)50
nd then declined approximately 5–20-fold by 6 months after
he ﬁnal dose. Titers at 6 months remained highest in the high
ose group. Titers were reported to be comparable to those inr is uncertain.
 are not included. Further development of those candidates also appears uncertain.
convalescent sera from CHIKV-infected patients. Phase II stud-
ies (clinicaltrials.gov NCT02562482) were scheduled to begin at
multiple sites in the Caribbean in October, 2015. Two other VLP
vaccine candidates, based on production from baculovirus-infected
insect cells expressing CHIKV structural proteins, have also been
evaluated in mouse models and shown to be immunogenic and
protective. VLP vaccines may face challenges with manufacturing
scale-up and optimization/improvements for production are being
investigated.
Phase I results were also recently reported for a vectored
recombinant measles virus (MV) expressing structural proteins
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C-E3-E2-6K-E1) from CHIKV strain 06-49 (Indian Ocean lin-
age) [19]. In mouse studies, MV-CHIK was immunogenic (PRNT50
iters of 450–4050; PRNT90 = 50–450) and protective following two
ntraperitoneal (i.p.) doses of 104 pfu or a single 105 pfu dose. MV-
HIK was evaluated in healthy 18–45 years old (yo) adults at three
ifferent dose levels (1.5 × 104, 7.5 × 104, or 3 × 105 TCID50) with-
ut adjuvant. Subjects received two immunizations delivered at
ays 0 and 28 or 0 and 90. Neutralizing antibodies (against CHIKV
train 181/25) were detected following the ﬁrst immunization in
ll dose groups (PRNT50 GMTs from 7 to 73) and increased follow-
ng boosting (PRNT50 GMTs from 63 to 433) with seroconversion in
00% of subjects. No signiﬁcant safety problems were reported and
he presence of pre-existing MV  immunity had no apparent effect
n neutralizing anti-CHIKV antibody responses from study volun-
eers. Phase II studies are planned for 2016. Additional candidates
ased on VSV, adenovirus or poxvirus (MVA) vectors expressing
HIKV structural proteins have been shown to be immunogenic
nd protective in mice following one or two doses and appear to
timulate strong cell mediated immunity to immunodominant CD8
pitopes in CHIKV structural proteins in addition to neutralizing
ntibodies. For one MVA-based candidate, expressing E2 & E3 pro-
eins only, protection against CHIKV challenge in A129 mice was
ot strongly associated with neutralizing antibody titers suggesting
hat CMI  was a more signiﬁcant factor. Phase I trials of a VSV-based
andidate are reported to have been planned for 2016.
Although chimeric CHIK vaccines based on other attenuated
lphavirus backbones have been investigated, the current leading
ive, attenuated candidates are rationally designed to limit poten-
ial for reversion to virulence and/or transmission by mosquito
ectors, through the use of alternative RNA transcription regulation
equences (CHIK/IRES) or deletions in nonstructural (CHIKV-
5nsP3) or structural (CHIKV-6K; TM17-2, with deletion in the
2 transmembrane domain;) genes. CHIK/IRES vaccines use an
CMV internal ribosome entry sequence (IRES) in place of the
ubgenomic promoter (v1) or to control capsid transcription. Both
ere highly attenuated in mice, stimulated humoral and CMI
esponses, and protected mice and NHPs against CHIKV challenge
ollowing single dose immunization (105 pfu i.m. or subcutaneously
s.c.] in NHPs). PRNT50 titers in NHPs at 7 weeks post-vaccination
ere 160–1280 and neutralizing antibodies appear to be the pri-
ary mediator of protection. The other live, attenuated candidates
lso induced CHIKV-speciﬁc neutralizing antibodies and/or CD8T
ell responses in C57BL/6 mice following a single dose (103 pfu
f TM17-2; 105 pfu of CHIKV-5nsP3 or CHIKV-6K) and pro-
ected against CHIKV challenge (reduced or absent viremia, and
educed footpad swelling). Peak NT50 titers for CHIKV-5nsP3
ere 102–104. Data from NHP studies with these alternative can-
idates have not been reported. CHIK/IRES, CHIKV-5nsP3 and
M17-2 have industry partners for development and are likely to
roceed to clinical evaluation.
Several inactivated candidates are in development, primarily by
anufacturers in India. Although little data has been published on
hese vaccines, a range of CHIKV strains (including wild-type iso-
ates and the US Army live attenuated 181/clone 25), cell lines for
roduction, inactivation and puriﬁcation methods, and formulation
ypes have been proposed some examples have been evaluated in
ouse models. All require 2 or 3 doses of 10–50 g of antigen to
nduce neutralizing antibodies and/or T cell responses. For exam-
le, a formalin-inactivated, alum adjuvanted vaccine, based on a
ero cell-adapted 2006 Indian isolate given as a three-dose sched-
le (days 0, 14 and 28) stimulated neutralizing antibodies in a
ose-dependent manner, with peak PRNT50 titers ≤ 6400 in 50 g
ohort. Clinical trials of at least one inactivated candidate may begin
n India during 2015–2016.
DNA vaccines, expressing CHIKV structural proteins, subge-
omic replicons or full-length live attenuated CHIKVs, and subunit
[4 (2016) 2976–2981
protein vaccines have also been evaluated in mice and/or NHPs,
including in heterologous prime-boost strategies. A plasmid encod-
ing full-length, live attenuated CHIKV 181/clone 25 induced robust
neutralizing antibodies (PRNT50 640–10,240; PRNT80 320–1280) in
BALB/c following a single i.m. 10 g dose. Other plasmids express-
ing CHIKV structural protein genes typically required multiple
doses but induced neutralizing antibodies at titers >100 and also
CHIKV-speciﬁc CD8T cell responses.
5. Likelihood for ﬁnancing
The recent acquisition of several leading chikungunya vaccine
candidates by mid- to large-size vaccine developers/manufacturers
suggests that a market is perceived to exist for these products, most
likely catalyzed by the advancing geographical spread of CHIKV.
Although chikungunya vaccines would have potential markets for
military or traveler use, the predominant need for a vaccine is
within LMIC. At least 9 countries with endemic chikungunya or
that have experienced epidemics in the past 10 years are eligi-
ble for GAVI ﬁnancing. Government support in many developing
countries will be necessary and may  only come as reactionary to
control chikungunya epidemics. India is perhaps at the forefront
of countries with endemic chikungunya to have government sup-
port ﬁnancially and for inclusion on their routine immunization
schedule should a vaccine become available. GAVI ﬁnancing will
ultimately depend on the cost-effectiveness of the vaccine given the
burden of disease and the likelihood for host country affordability
and sustainability.
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